Company |
Date |
Date |
Shares/ |
Price |
Shares |
Lead, other |
Gross |
Post- |
INITIAL OFFERINGS TOTAL: $194.4M | ||||||||
Audentes Therapeutics Inc. (San Francisco; BOLD) |
1/4/16 |
7/21/16 |
5S |
$15 |
N/A |
BofA Merrill Lynch; Cowen and Co.; Piper Jaffray |
$75.00 |
N/A |
Gensight Biologics SA (Paris; EPA:SIGHT) |
7/14/16 |
7/14/16 |
18.6S |
$8.89 |
N/A |
N/A |
$44.40 |
€ 149.00 |
Kadmon Holdings LLC (New York; NYSE:KDMN)1 |
6/13/16 |
7/28/16 |
6.25S |
$12 |
N/A |
Citigroup Global Markets; Jefferies; JMP Securities; H.C. Wainwright & Co. |
$75 |
N/A |
|
Number of IPOs in July: 3 Average value of July IPOs: $64.8M Number of IPOs in 2016: 23 Total raised in IPOs in 2016: $1,457.82M Average value of IPOs in 2016: $63.38M | ||||||||
FOLLOW-ON OFFERINGS TOTAL: $1,333.84M | ||||||||
Argos Therapeutics Inc. (Durham, N.C.; ARGS) |
5/14/15 |
7/29/16 |
9S and W for 6.8S |
$5.50 |
41.100 |
Stifel (co-lead); JMP Securities (co-lead); Needham; FBR; Roth Capital Partners |
$50.00 |
$226.05 |
Cardiome Pharma Corp. (Vancouver, British Columbia; CRME)2 |
7/26/16 |
7/27/16 |
11.5S |
$3.00 |
N/A |
Leerink Partners (lead); Canaccord Genuity; H.C. Wainwright; Cormark Securities |
$34.50 |
N/A |
Contrafect Corp. (Yonkers, N.Y.; CFRX) |
6/8/16 |
7/25/16 |
14S and W for 14S |
$2.50 |
41.5 |
Piper Jaffray; William Blair |
$35.00 |
$103.75 |
Cytrx Corp. (Los Angeles; CYTR) |
6/17/16 |
7/18/16 |
28.6S and W for 28.6S |
$0.70 |
123.7 |
Rodman & Renshaw |
$20.00 |
$86.59 |
GW Pharmaceuticals plc (London)3 |
5/7/14 |
7/14/16 |
3.22ADS |
$90.00 |
296.5 |
Morgan Stanley; BofA Merrill Lynch; Goldman Sachs; Cowen and Co.; Piper Jaffray |
$289.80 |
$2,223.75 |
Intercept Pharmaceuticals Inc. (New York; ICPT)4 |
4/1/14 |
7/1/16 |
Notes |
$1,000 |
N/A |
RBC Capital Markets; UBS Investment Bank; BofA Merrill Lynch; Citigroup; Credit Suisse |
$460.00 |
N/A |
Kitov Pharmaceuticals Ltd. (Tel Aviv, Israel; KTOV)5 |
6/30/16 |
7/1/16 |
2.37U |
$3.40 |
130.07 |
Rodman & Renshaw; Joseph Gunnar |
$12.00 |
N/A |
Tesaro Inc. (Waltham, Mass.; TSRO)6 |
6/30/16 |
7/5/16 |
5.34S |
$81.00 |
50.06 |
Citigroup; Leerink Partners; Credit Suisse; Wells Fargo Securities; Guggenheim Securities; Mizuho; Raymond James; Suntrust Robinson Humphrey; Wedbush Pacgrow |
$432.54 |
$4,054.86 |
|
Number of follow-on offerings in July: 8 Average value of July follow-ons: $55.35M Number of follow-on offerings in 2016: 64 Total raised in follow-ons in 2016: $4,495.15M Average value of follow-ons in 2016: $70.24M | ||||||||
|
Notes # Unless otherwise indicated, shares are traded on the Nasdaq exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. This chart includes only biotech companies that develop therapeutics. 1 Kadmon Holdings' overallotment option: 937,500 shares. 2 Includes Cardiome Pharma's overallotment option: 1.5M shares. 3 Includes GW's overallotment option: 420,000 ADSs 4 Intercept priced its public offering of $400M aggregate principal amount of 3.25% convertible senior notes due 2023; includes overallotment option: $60M of the notes. 5 Kitov priced its public offering of 2.37M class A units, consisting of one American Depositary share (ADS) and a warrant to purchase one ADS, as well as 1.15M class B units at $3.40 per unit, consisting of a non-listed, pre-funded warrant to purchase one ADS, and a listed warrant. 6 Includes Tesaro's overallotment option: 697,500 shares. | ||||||||